Companies Nevro
Nevro (NVRO): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Nevro no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers67th pct.Of 17 peer CEOs
CEO pay, last three years
- $11,453,548FY2023
CEO total pay was $11,453,548 in fiscal 2023; the brief holds no earlier figure for this CEO.
FY2023: salary $515,625 · bonus $0 · stock awards $10,080,173 · option awards $0
Executives and directors
D. Keith Grossman · ExecutiveGreg Siller · CCOKashif Rashid · General CounselKevin Thornal · CEORoderick MacLeod · CFONiamh Pellegrini · CCOElizabeth Weatherman · Independent DirectorFrank Fischer · Independent DirectorKaren Prange · Independent DirectorKevin O'Boyle · Independent DirectorKirt P. Karros · Independent DirectorMichael DeMane · Lead Independent DirectorShawn T McCormick · Independent DirectorSri Kosaraju · Independent DirectorSusan Siegel · Independent Director
Frequently asked questions
Who was the highest-paid executive at Nevro in fiscal 2023?
As disclosed, Kevin Thornal (President and Chief Executive Officer) was the highest-paid executive at Nevro in fiscal 2023, with total compensation of $11,453,548.
How does Nevro's chief executive pay compare to its disclosed peer group?
As disclosed, Kevin Thornal's total compensation ranked at the 67th percentile of Nevro's disclosed peer group.
How did shareholders vote on Nevro's executive compensation?
As disclosed, 95.23% of shareholders supported Nevro's executive compensation in the latest say-on-pay vote.
How much does Nevro spend in total on board compensation for fiscal 2023?
As disclosed, Nevro reported total board compensation of $2,037,202 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Thornal | $515,625 | $0 | $10,080,173 | $0 | $402,750 | $0 | $455,000 | $11,453,548 |
| President and Chief Executive Officer | ||||||||
| Niamh Pellegrini | 272,020 | 0 | 1,924,076 | 0 | 0 | 0 | 2,713,525 | 4,909,622 |
| Former Senior Vice President and Chief Commercial Officer | ||||||||
| Greg Siller | 242,045 | 0 | 3,138,205 | 0 | 77,858 | 0 | 100,000 | 3,558,108 |
| Senior Vice President and Chief Commercial Officer | ||||||||
| Roderick MacLeod | 490,170 | 0 | 1,924,076 | 0 | 157,933 | 0 | 5,000 | 2,577,179 |
| Senior Vice President and Chief Financial Officer | ||||||||
| Kashif Rashid | 472,410 | 0 | 1,924,076 | 0 | 152,211 | 0 | 5,000 | 2,553,697 |
| Senior Vice President, Corporate Development and Chief Legal Officer | ||||||||
| D. Keith Grossman | 566,306 | 0 | 774,081 | 0 | 0 | 0 | 24,022 | 1,364,410 |
| Chairman, Former President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Kevin Thornal | $11,453,548 | — | — | — |
| Niamh Pellegrini | 4,909,622 | 3,681,384 | 2,756,726 | ↑ +1,228,238 |
| Greg Siller | 3,558,108 | — | — | — |
| Roderick MacLeod | 2,577,179 | 2,737,397 | 2,499,176 | ↓ −160,218 |
| Kashif Rashid | 2,553,697 | 3,240,217 | 2,128,747 | ↓ −686,520 |
| D. Keith Grossman | 1,364,410 | 17,769,126 | 7,402,510 | ↓ −16,404,716 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The key objective in our executive compensation program is to attract, motivate and reward leaders with the skills and experience necessary to successfully execute on our strategic plan to maximize stockholder value. The program is designed to align the long-term interests of our NEOs with those of our stockholders and provide reward opportunities consistent with our performance on both a short-term and long-term basis.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Roderick MacLeod | PSU | 2023-03-07 | 2,104 | 16,835 | — | 33,670 | $654,875 |
| Niamh Pellegrini | PSU | 2023-03-07 | 2,104 | 16,835 | — | 33,670 | 654,875 |
| Kashif Rashid | PSU | 2023-03-07 | 2,104 | 16,835 | — | 33,670 | 654,875 |
| Niamh Pellegrini | RSU | 2023-03-07 | — | — | 39,282 | — | 1,269,201 |
| Greg Siller | RSU | 2023-06-19 | — | — | 82,050 | — | 2,066,019 |
| Greg Siller | PSU | 2023-06-19 | 4,395 | 35,165 | — | 70,330 | 1,072,186 |
| Kashif Rashid | RSU | 2023-03-07 | — | — | 39,282 | — | 1,269,201 |
| Kevin Thornal | PSU | 2023-04-24 | 16,952 | 135,623 | — | 271,246 | 5,483,909 |
| D. Keith Grossman | RSU | 2023-04-24 | — | — | 22,841 | — | 774,081 |
| Roderick MacLeod | RSU | 2023-03-07 | — | — | 39,282 | — | 1,269,201 |
| Kevin Thornal | RSU | 2023-04-24 | — | — | 135,623 | — | 4,596,263 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Roderick MacLeod | $1,269,201 | $654,875 | $0 | 34.0% |
| Niamh Pellegrini | 1,269,201 | 654,875 | 0 | 34.0% |
| Kashif Rashid | 1,269,201 | 654,875 | 0 | 34.0% |
| Greg Siller | 2,066,019 | 1,072,186 | 0 | 34.2% |
| Kevin Thornal | 4,596,263 | 5,483,909 | 0 | 54.4% |
| D. Keith Grossman | 774,081 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Roderick MacLeod | PSU | 1,212 | — | $26,082 |
| Kashif Rashid | PSU | 1,212 | — | 26,082 |
| Kashif Rashid | RSU | 1,249 | — | 26,878 |
| Roderick MacLeod | RSU | 3,013 | — | 64,840 |
| Kashif Rashid | RSU | 3,568 | — | 76,783 |
| Roderick MacLeod | RSU | 4,307 | — | 92,687 |
| Kashif Rashid | RSU | 7,140 | — | 153,653 |
| Roderick MacLeod | RSU | 7,603 | — | 163,617 |
| Kashif Rashid | RSU | 7,603 | — | 163,617 |
| D. Keith Grossman | PSU | 7,750 | — | 166,780 |
| D. Keith Grossman | RSU | 8,098 | — | 174,269 |
| Roderick MacLeod | PSU | 8,418 | — | 181,155 |
| Kashif Rashid | PSU | 8,418 | — | 181,155 |
| D. Keith Grossman | RSU | 10,477 | — | 225,465 |
| Greg Siller | PSU | 17,582 | — | 378,365 |
| Roderick MacLeod | RSU | 39,282 | — | 845,349 |
| Kashif Rashid | RSU | 39,282 | — | 845,349 |
| D. Keith Grossman | RSU | 50,000 | — | 1,076,000 |
| D. Keith Grossman | PSU | 50,000 | — | 1,076,000 |
| Kevin Thornal | PSU | 67,812 | — | 1,459,314 |
| Greg Siller | RSU | 82,050 | — | 1,765,716 |
| Kevin Thornal | RSU | 135,623 | — | 2,918,607 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael DeManeIndependent · Lead Independent Director | $105,000 | $179,994 | $0 | $0 | $0 | $284,994 |
| Kevin O'BoyleIndependent · Audit | 80,000 | 179,994 | 0 | 0 | 0 | 259,994 |
| Elizabeth WeathermanIndependent · Audit · Nominating and Governance · Compensation | 79,250 | 179,994 | 0 | 0 | 0 | 259,244 |
| Karen PrangeIndependent · Audit · Nominating and Governance · Compensation | 73,000 | 179,994 | 0 | 0 | 0 | 252,994 |
| Frank FischerIndependent · Nominating and Governance · Not standing for re-election | 67,000 | 179,994 | 0 | 0 | 0 | 246,994 |
| Shawn T McCormickIndependent · Audit | 67,000 | 179,994 | 0 | 0 | 0 | 246,994 |
| Sri KosarajuIndependent · Compensation | 63,000 | 179,994 | 0 | 0 | 0 | 242,994 |
| Susan SiegelIndependent · Compensation · Nominating and Governance · Technology | 63,000 | 179,994 | 0 | 0 | 0 | 242,994 |
| D. Keith GrossmanIndependent · Board Chair | 0 | 0 | 0 | 0 | 0 | 0 |
| Kevin ThornalEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Kirt P. KarrosIndependent · Audit · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $180,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 13,000 / 10,250 / 6,000 |
| Stock ownership guideline | 3x base annual retainer |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $597,250 |
| Equity awards (grant-date value) | $1,439,952 |
| All other compensation | $0 |
| Total cost of the board | $2,037,202 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Nevro as a peer
Companies that benchmark against NVRO
22 companies name NVRO as a compensation peer
The list of companies that name NVRO as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ATEC Alphatec HoldingsHAE HaemoneticsPEN PenumbraCSII Cardiovascular SystemsTNDM Tandem Diabetes CareANGO AngioDynamicsNTRA NateraATRC AtriCureNUVA NuVasiveNVCR NovoCureGKOS GlaukosIART Integra LifeSciencesAXNX AxonicsIRTC iRhythm TechnologiesGMED Globus MedicalMASI MasimoOFIX Orthofix Medical
Peer reciprocity
The companies Nevro names as compensation peers that name it back in their own disclosed peer groups.
Alphatec Holdings (ATEC)105Tandem Diabetes Care (TNDM)106AngioDynamics (ANGO)107AtriCure (ATRC)108NuVasive (NUVA)109Orthofix Medical (OFIX)110
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Masimo | 2025 | Catherine Szyman | $850,048 | $16,388,693 | $1,399,998 | $1,130,000 | $19,797,140 |
| 2 | Natera | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 3 | NovoCure | 2025 | Ashley Cordova | 901,837 | 8,249,965 | 2,752,814 | 811,653 | 13,198,354 |
| 4 | Haemonetics | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 5 | Glaukos | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 6 | Nevro | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 7 | iRhythm Technologies | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 8 | Alphatec Holdings | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 9 | Integra LifeSciences | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 10 | AtriCure | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 11 | NuVasive | 2022 | J. Christopher Barry | 896,635 | 5,000,093 | 0 | 2,157,750 | 8,077,095 |
| 12 | Orthofix Medical | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 13 | Tandem Diabetes Care | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 14 | AngioDynamics | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 15 | Globus Medical | 2025 | Keith Pfeil | 479,467 | 0 | 2,982,347 | 783,000 | 4,400,159 |
| 16 | Penumbra | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
| — | Cardiovascular Systems | — | — | — | — | — | — | not in coverage universe |
| — | Axonics | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Nevro | 53.7% | not disclosed | No | Aon |
| Alphatec Holdings | 157% | PSU 50 · RSU 50 | No | Compensia |
| AngioDynamics | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| AtriCure | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| Axonics | not disclosed | not disclosed | not disclosed | not disclosed |
| Cardiovascular Systems | not disclosed | not disclosed | not disclosed | not disclosed |
| Glaukos | not disclosed | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Globus Medical | 102% | Options 100 | not disclosed | FW Cook |
| Haemonetics | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Integra LifeSciences | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| iRhythm Technologies | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| Masimo | not disclosed | not disclosed | not disclosed | FW Cook |
| Natera | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NovoCure | 100% | PSU 50 · RSU 25 · Options 25 | No | Frederic W. Cook & Co., Inc. |
| NuVasive | 75% | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Orthofix Medical | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| Penumbra | not disclosed | not disclosed | No | Compensia |
| Tandem Diabetes Care | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-05-23 | 28,039,355 | 1,403,078 | 6,094 | 95.23% | Passed |
| 2023 | 2023-05-25 | 8,273,380 | 21,017,829 | 20,362 | 28.25% | Failed |
| 2022 | 2022-05-26 | 25,590,117 | 5,163,788 | 24,177 | 83.21% | Passed |
| 2021 | 2021-05-25 | 26,726,634 | 4,785,359 | 8,306 | 84.81% | Passed |
| 2020 | 2020-05-21 | 25,225,657 | 1,581,703 | 33,199 | 94.1% | Passed |
| 2019 | 2019-05-20 | 20,131,096 | 4,427,238 | 38,662 | 81.97% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-05-23 | 95.23%a |
| 2023 | 2023-05-25 | 28.25%b |
| 2022 | 2022-05-26 | 83.21%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Elizabeth Weatherman | Director | 2024-12-31 | A | 5,325 | $0 | $0 | Common | Form 4 ↗ |
| Michael DeMane | Director | 2024-12-31 | A | 7,056 | 0 | 0 | Common | Form 4 ↗ |
| Sri Kosaraju | Director | 2024-12-31 | A | 4,233 | 0 | 0 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-01-04 | D | 527 | 4 | 1,955 | Common | Form 4 ↗ |
| Kevin Thornal | Director | 2025-01-24 | D | 6,685 | 5 | 34,495 | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-02-28 | D | 805 | 6 | 4,605 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-02-28 | D | 392 | 6 | 2,242 | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-02-28 | D | 642 | 6 | 3,672 | Common | Form 4 ↗ |
| D. Keith Grossman | Director | 2025-02-28 | A | 4,750 | 0 | 0 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-02-28 | D | 825 | 6 | 4,719 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-02-28 | A | 742 | 0 | 0 | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-02-28 | D | 392 | 6 | 2,242 | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-02-28 | A | 742 | 0 | 0 | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-02-28 | D | 313 | 6 | 1,790 | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-02-28 | A | 530 | 0 | 0 | Common | Form 4 ↗ |
| D. Keith Grossman | Director | 2025-02-28 | D | 1,071 | 6 | 6,126 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-03-02 | D | 944 | 6 | 5,400 | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-03-02 | D | 1,143 | 6 | 6,538 | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-03-02 | D | 800 | 6 | 4,576 | Common | Form 4 ↗ |
| D. Keith Grossman | Director | 2025-03-03 | D | 1,017 | 6 | 5,817 | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-03-07 | D | 1,328 | 6 | 7,663 | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-03-07 | D | 15,136 | 6 | 87,335 | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-03-07 | D | 1,763 | 6 | 10,173 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-03-07 | D | 15,136 | 6 | 87,335 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-03-07 | D | 1,758 | 6 | 10,144 | Common | Form 4 ↗ |
| Kevin Thornal | Director | 2025-03-07 | D | 27,029 | 6 | 155,957 | Common | Form 4 ↗ |
| Greg Siller | SVP & Chief Commercial Officer | 2025-03-07 | D | 11,500 | 6 | 66,355 | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-03-07 | D | 11,333 | 6 | 65,391 | Common | Form 4 ↗ |
| D. Keith Grossman | Director | 2025-03-11 | D | 1,641 | 6 | 9,485 | Common | Form 4 ↗ |
| Greg Siller | SVP & Chief Commercial Officer | 2025-03-19 | D | 3,083 | 6 | 17,820 | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-03-20 | A | 852 | 0 | 0 | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-03-20 | D | 611 | 6 | 3,532 | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-03-20 | A | 1,136 | 0 | 0 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-03-20 | D | 611 | 6 | 3,532 | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-03-20 | D | 458 | 6 | 2,647 | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-03-20 | A | 1,136 | 0 | 0 | Common | Form 4 ↗ |
| Susan Siegel | Director | 2025-04-03 | D | 24,579 | — | — | Common | Form 4 ↗ |
| Michael DeMane | Director | 2025-04-03 | D | 61,863 | — | — | Common | Form 4 ↗ |
| Shawn T McCormick | Director | 2025-04-03 | D | 46,035 | — | — | Common | Form 4 ↗ |
| Sri Kosaraju | Director | 2025-04-03 | D | 46,575 | — | — | Common | Form 4 ↗ |
| Christofer Christoforou | SVP, Chief Operating Officer | 2025-04-03 | D | 363,765 | — | — | Common | Form 4 ↗ |
| Roderick MacLeod | SVP, Chief Financial Officer | 2025-04-03 | D | 350,663 | — | — | Common | Form 4 ↗ |
| Kevin C. Oboyle | Director | 2025-04-03 | D | 43,396 | — | — | Common | Form 4 ↗ |
| D. Keith Grossman | Director | 2025-04-03 | D | 228,552 | — | — | Common | Form 4 ↗ |
| Kashif Rashid | SVP, Corp Dev and CLO | 2025-04-03 | D | 477,738 | — | — | Common | Form 4 ↗ |
| Greg Siller | SVP & Chief Commercial Officer | 2025-04-03 | D | 195,598 | — | — | Common | Form 4 ↗ |
| Michael DeMane | Director | 2025-04-03 | D | 58,266 | — | — | Common | Form 4 ↗ |
| Michael DeMane | Director | 2025-04-03 | D | 219,145 | — | — | Common | Form 4 ↗ |
| Michael DeMane | Director | 2025-04-03 | D | 164,344 | — | — | Common | Form 4 ↗ |
| Karen Prange | Director | 2025-04-03 | D | 33,948 | — | — | Common | Form 4 ↗ |
| Kevin Thornal | Director | 2025-04-03 | D | 852,337 | — | — | Common | Form 4 ↗ |
| Kirt P. Karros | Director | 2025-04-03 | D | 17,452 | — | — | Common | Form 4 ↗ |
| Susan Siegel | Director | 2025-04-03 | D | 7,382 | — | — | Common | Form 4 ↗ |
| Elizabeth Weatherman | Director | 2025-04-03 | D | 86,171 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (110 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kevin Thornal. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION TABLES” · page 36. As printed: 11,453,548. View filing ↗
- Section 01, Niamh Pellegrini. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION TABLES” · page 36. As printed: 4,909,622. View filing ↗
- Section 01, Greg Siller. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION TABLES” · page 36. As printed: 3,558,108. View filing ↗
- Section 01, Roderick MacLeod. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION TABLES” · page 36. As printed: 2,577,179. View filing ↗
- Section 01, Kashif Rashid. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION TABLES” · page 36. As printed: 2,553,697. View filing ↗
- Section 01, D. Keith Grossman. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION TABLES” · page 36. As printed: 1,364,410. View filing ↗
- Section 03, Roderick MacLeod PSU. DEF 14A, filed 2024-04-12. Section “2023 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Niamh Pellegrini PSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kashif Rashid PSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Niamh Pellegrini RSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Greg Siller RSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Greg Siller PSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kashif Rashid RSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Thornal PSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, D. Keith Grossman RSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Roderick MacLeod RSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Thornal RSU. DEF 14A, filed 2024-04-12. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 08, Michael DeMane. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 284,994. View filing ↗
- Section 08, Kevin O'Boyle. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 259,994. View filing ↗
- Section 08, Elizabeth Weatherman. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 259,244. View filing ↗
- Section 08, Karen Prange. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 252,994. View filing ↗
- Section 08, Frank Fischer. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 246,994. View filing ↗
- Section 08, Shawn T McCormick. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 246,994. View filing ↗
- Section 08, Sri Kosaraju. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 242,994. View filing ↗
- Section 08, Susan Siegel. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 242,994. View filing ↗
- Section 08, D. Keith Grossman. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Kevin Thornal. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Kirt P. Karros. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Elizabeth Weatherman 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael DeMane 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sri Kosaraju 2024-12-31. Form 4, filed 2025-01-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-01-04. Form 4, filed 2025-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Thornal 2025-01-24. Form 4, filed 2025-01-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Keith Grossman 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Keith Grossman 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-03-02. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-03-02. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-03-02. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Keith Grossman 2025-03-03. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-03-07. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-03-07. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-03-07. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-03-07. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-03-07. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Thornal 2025-03-07. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Greg Siller 2025-03-07. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-03-07. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Keith Grossman 2025-03-11. Form 4, filed 2025-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Greg Siller 2025-03-19. Form 4, filed 2025-03-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Siegel 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael DeMane 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shawn T McCormick 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sri Kosaraju 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christofer Christoforou 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roderick MacLeod 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin C. Oboyle 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Keith Grossman 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kashif Rashid 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Greg Siller 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael DeMane 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael DeMane 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael DeMane 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Prange 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Thornal 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kirt P. Karros 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Siegel 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Weatherman 2025-04-03. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-29. Item 5.07 · say-on-pay result. As reported: 95.23% (votes for as printed: 28,039,355). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-30. Item 5.07 · say-on-pay result. As reported: 28.25% (votes for as printed: 8,273,380). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-05-31. Item 5.07 · say-on-pay result. As reported: 83.21% (votes for as printed: 25,590,117). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 597,250 + equity 1,439,952 + all other 0 = 2,037,202, summed across the director compensation table rows.
- Masimo, Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo's own proxy. As printed: 19,797,140. View filing ↗
- Natera, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. View filing ↗
- NovoCure, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in NovoCure's own proxy. As printed: 13,198,354. View filing ↗
- Haemonetics, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics's own proxy. As printed: 12,044,701. View filing ↗
- Glaukos, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. View filing ↗
- Nevro (subject), Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. View filing ↗
- iRhythm Technologies, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Technologies's own proxy. As printed: 11,003,163. View filing ↗
- Alphatec Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings's own proxy. As printed: 10,260,507. View filing ↗
- Integra LifeSciences, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integra LifeSciences's own proxy. As printed: 9,375,551. View filing ↗
- AtriCure, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure's own proxy. As printed: 9,217,620. View filing ↗
- NuVasive, Section 10b CEO total. DEF 14A, filed 2023-05-08. CEO total compensation as printed in NuVasive's own proxy. As printed: 8,077,095. View filing ↗
- Orthofix Medical, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orthofix Medical's own proxy. As printed: 7,310,039. View filing ↗
- Tandem Diabetes Care, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care's own proxy. As printed: 6,858,503. View filing ↗
- AngioDynamics, Section 10b CEO total. DEF 14A, filed 2026-10-08. CEO total compensation as printed in AngioDynamics's own proxy. As printed: 6,060,145. View filing ↗
- Globus Medical, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Globus Medical's own proxy. As printed: 4,400,159. View filing ↗
- Penumbra, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Penumbra's own proxy. As printed: 851,621. View filing ↗
- Section 10a, Alphatec Holdings reciprocity. DEF 14A. Alphatec Holdings names Nevro in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Tandem Diabetes Care reciprocity. DEF 14A. Tandem Diabetes Care names Nevro in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, AngioDynamics reciprocity. DEF 14A. AngioDynamics names Nevro in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, AtriCure reciprocity. DEF 14A. AtriCure names Nevro in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, NuVasive reciprocity. DEF 14A. NuVasive names Nevro in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Orthofix Medical reciprocity. DEF 14A. Orthofix Medical names Nevro in its own disclosed peer group (read from its most recent proxy). View filing ↗